Associated Papers
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Bruckmueller H et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism.
Mejía-Abril G et al.
Frontiers in Pharmacology, 2021
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
[Single nucleotide polymorphisms in lung cancer patients and cisplatin treatment].
Stenzel-Bembenek A et al.
Postepy Higieny I Medycyny Doswiadczalnej (online), 2014
Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.
Paulík A et al.
Acta Medica (hradec Kralove), 2012
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K et al.
Cancer Chemotherapy and Pharmacology, 2010
MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer.
Komoto C et al.
Drug Metabolism and Pharmacokinetics, 2006
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.
Dey S
Expert Opinion on Drug Delivery, 2006
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Bosch TM et al.
Molecular Diagnosis & Therapy, 2006
Select a paper to view details